The British Journal of Cardiology

This site is intended for UK healthcare professionals

 
BJC_tv_logo_white
Sign in

Three Sponsors

The barriers to early diagnosis of cardiac amyloidosis in women

In this short video, Professor Fontana discusses the barriers women face in the diagnosis of cardiac amyloidosis.

This non-promotional video has been developed and funded by Pfizer Ltd. and is intended for UK healthcare professionals only.
PP-UNP-GBR-14083 | March 2026

British Society of Echocardiography guideline for the TTE assessment of cardiac amyloidosis and the role of ECHO in monitoring disease progression in cardiac amyloidosis

In this short video, Dr Moody discusses the British Society of Echocardiography guidelines for the TTE assessment of cardiac amyloidosis, and monitoring disease progression.

This non-promotional video has been developed and funded by Pfizer Ltd. and is intended for UK healthcare professionals only.
PP-UNP-GBR-14077 | March 2026

Hiding in plain sight – a case-based overview of amyloidosis

Experts from the National Amyloidosis Centre in London examine three case studies, specifically focusing upon the symptoms that first aroused suspicion, the diagnostic tests that confirmed the condition, and the treatment options available to these patients.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence.

Amyloidosis: a comprehensive guide for the cardiovascular team

A guide for all members of the cardiovascular and primary care teams on what to look for, and what to do if you suspect amyloidosis: signs and symptoms, diagnostic tests and studies, and the treatment options currently available.

Funding for this video has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found on the video page.

ESC Congress 2024 highlights – A UK perspective: What’s new in the latest ESC guideline update?

Dr Paul Foley and Prof Terry McCormack share the key changes in the new ESC guidance on atrial fibrillation, hypertension and arterial disease.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

ESC Congress 2024 highlights – A UK perspective: New evidence on cardiovascular medical care

Dr Sarah Birkhoelzer and Dr Aaron Henry discuss hot topics and late-breaking abstracts from across the congress.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.